News stories about Aquinox Pharmaceuticals (NASDAQ:AQXP) have trended somewhat positive on Wednesday, Accern reports. Accern identifies positive and negative press coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Aquinox Pharmaceuticals earned a news sentiment score of 0.18 on Accern’s scale. Accern also assigned news headlines about the company an impact score of 45.7539147134263 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
Here are some of the news headlines that may have effected Accern’s rankings:
- Aquinox Pharmaceuticals Inc (AQXP) COO Sells $19,048.26 in Stock (americanbankingnews.com)
- Aquinox Pharmaceuticals (AQXP) Stock Rating Lowered by Zacks Investment Research (americanbankingnews.com)
- Aquinox Pharmaceuticals Inc to Post FY2018 Earnings of ($2.27) Per Share, Cantor Fitzgerald Forecasts (AQXP) (americanbankingnews.com)
- Aquinox Pharmaceuticals Inc (AQXP) to Post FY2019 Earnings of ($1.59) Per Share, Cantor Fitzgerald Forecasts (americanbankingnews.com)
- Analysis of 52-week high on Aquinox Pharmaceuticals, Inc. (AQXP) – The Stocks News (press release) (thestocksnews.com)
A number of equities research analysts have commented on AQXP shares. Zacks Investment Research upgraded shares of Aquinox Pharmaceuticals from a “hold” rating to a “buy” rating and set a $13.00 target price on the stock in a research note on Tuesday, January 9th. Canaccord Genuity set a $22.00 target price on shares of Aquinox Pharmaceuticals and gave the stock a “buy” rating in a research note on Tuesday, December 19th. Cantor Fitzgerald restated a “buy” rating and set a $28.00 target price on shares of Aquinox Pharmaceuticals in a research note on Sunday, February 11th. Guggenheim started coverage on shares of Aquinox Pharmaceuticals in a research note on Thursday, February 8th. They set a “buy” rating and a $26.00 target price on the stock. Finally, BidaskClub upgraded shares of Aquinox Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, February 14th. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus price target of $22.80.
Aquinox Pharmaceuticals (NASDAQ:AQXP) last announced its quarterly earnings data on Monday, March 12th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.10). sell-side analysts anticipate that Aquinox Pharmaceuticals will post -2.27 EPS for the current year.
TRADEMARK VIOLATION NOTICE: This piece of content was published by BBNS and is owned by of BBNS. If you are viewing this piece of content on another site, it was stolen and republished in violation of U.S. and international copyright legislation. The legal version of this piece of content can be viewed at https://baseballnewssource.com/2018/03/21/somewhat-positive-press-coverage-somewhat-unlikely-to-affect-aquinox-pharmaceuticals-aqxp-share-price/2028001.html.
Aquinox Pharmaceuticals Company Profile
Aquinox Pharmaceuticals, Inc is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company’s primary focus is anti-inflammatory product candidates targeting the Src Homology 2 (SH2)-containing inositol-5-phosphatase 1 (SHIP1) enzyme, which is a regulator of a cellular signaling pathway in immune cells, known as the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) pathway.
Receive News & Ratings for Aquinox Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquinox Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.